Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment 0 17.12.2024 19:51 The Wall Street Journal Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
